Tags : Top

Top 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More

Top 20

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at […]Read More

Top 20

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced, effective, and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top […]Read More

Insights+

Insights+: Novel Drug Approvals by the US FDA in 2018

1.Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Published: 14 Feb,2018 | Tags: Janssen, Erleada, apalutamide, Receives, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, NM-CRPC 2. Helsinn’s (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV) Published: 14 Feb,2018 | Tags: Helsins, fosnetupitant + palonosetron, Receives, FDA, Approval, […]Read More

Biosimilars Insights+

PharmaShots Year in Review: Biosimilars Approvals in 2018

  THE US FDA APPROVALS    1.  Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia Published: 15 May, 2018  | Tags: Pfizer, Retacrit, epoetinalfa-epbx, biosimilar, Receives, FDA, Approval, Anemia   2.   Pfizer’s Nivestym (filgrastim-aafi, biosmilar) Receives FDA Approval forNeutropenia   Published: 20 Jul, 2018 | Tags: (filgrastim-aafi approval biosmilar), Neutropenia, Nivestym, Pfizer, Receives, the […]Read More

Insights+

PharmaShots Year in Review 2018

 PharmaShots Year in Review | Top 10 Pharma News of 2018  1. Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology Portfolio Published: 22 Jan, 2018 | Tags: Celgene,  Acquire, Juno, Cellular, Immunotherapy, Hematology Portfolio 2.  Sanofi to Acquire Bioverativ for its Hemophilia Products Published: 22 Jan, 2018 | Tags: Sanofi, Acquire, Bioverativ, Treat, […]Read More